Clinical Trial Update: IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating IgG level when switching from standard SCIG to every-other-week HyQvia in patients with primary immunodeficiency; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)

Snippet

Sponsor: University Hospital, Lille | Conditions: Primary Immunodeficiency | Phase 4 | Status: COMPLETED